ConductScience.org, home
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
API referenceFor AI assistants

Trial · NCT03987074

Results by group25

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 25

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Semaglutide81.0percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Semaglutide + Firsocostat 20 mg86.4percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Semaglutide + Cilofexor 30 mg81.8percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Semaglutide + Cilofexor 100 mg72.7percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg90.5percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutideGrade 161.9percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Firsocostat 20 mgGrade 163.6percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Cilofexor 30 mgGrade 136.4percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Cilofexor 100 mgGrade 150.0percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Firsocostat 20 mg + Cilofexor 30 mgGrade 166.7percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutideGrade 223.8percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Firsocostat 20 mgGrade 222.7percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Cilofexor 30 mgGrade 231.8percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Cilofexor 100 mgGrade 218.2percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Firsocostat 20 mg + Cilofexor 30 mgGrade 29.5percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutideGrade 30.0percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Firsocostat 20 mgGrade 34.5percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Cilofexor 30 mgGrade 30.0percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Cilofexor 100 mgGrade 30.0percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesSemaglutide + Firsocostat 20 mg + Cilofexor 30 mgGrade 30.0percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03987074/results

API referenceFor AI assistants